Unlock instant, AI-driven research and patent intelligence for your innovation.

A pharmaceutical composition containing urate oxidase and its preparation method

A uric acid oxidase and composition technology, which is applied in the directions of medical preparations containing active ingredients, drug combinations, and non-active ingredients medical preparations, etc., can solve inflammatory reactions, recurrent gout attacks, and the inability of PEGylated uric acid oxidase to enter. And other issues

Active Publication Date: 2015-12-09
BEIJING TIDE PHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008]However, in recent years, studies have found that PEGylated urate oxidase rapidly degrades blood uric acid in the body, dissolving tophi and bringing small gout crystals to diffuse from the tophi Then, it binds to the signaling molecules in the immune cells, causing a severe inflammatory response, leading to repeated attacks of gout
These defects and deficiencies limit the clinical application of PEGylated urate oxidase
[0009] Chinese patent application CN101302501B, the title of the invention is "pegylated uric acid oxidase compound and its preparation method and its preparation and application", which discloses the preparation and use of pegylated urate oxidase, and the PEGylated uric acid obtained by this method Oxidase cannot enter the cell to metabolize the uric acid crystals in the cell, and it is easy to cause the above-mentioned inflammatory reaction, leading to repeated attacks of gout, which brings pain to the patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition containing urate oxidase and its preparation method
  • A pharmaceutical composition containing urate oxidase and its preparation method
  • A pharmaceutical composition containing urate oxidase and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Example 1 UOX derived from Candida

[0085] (1) Preparation of PC-UOX composition

[0086] Add 30 mL of boric acid buffer (50 mM boric acid, 50 mM potassium chloride) containing 1 mg / mL of Candida-derived UOX to a 100 mL reagent bottle at pH 8.5, and place at 4°C.

[0087] Refined lecithin (0.012 g) with a purity greater than 98% was dissolved in 6 mL of isopropanol to prepare a lecithin solution. The solution temperature was 4°C. 6 mL of this lecithin solution was added dropwise to the aforementioned UOX solution at a rate of 1 mL / min, and the solution obtained by stirring at 50 rpm for 4 hours was used as a reaction solution.

[0088] The reaction solution was added to a G-25 desalting column equilibrated with carbonate buffer (20 mM pH10.5 sodium carbonate-sodium bicarbonate buffer, 100 mM sodium chloride, 0.1% Tween-20) for desalting and buffer exchange. The obtained solution was added to an anion exchange column equilibrated with carbonate buffer (20 mM pH10.5 s...

Embodiment 2

[0104] The UOX of embodiment 2 Aspergillus flavus origin

[0105] (1) Preparation example of PC-UOX composition

[0106] Add 30 mL of pH 8.0 boric acid buffer (50 mM boric acid, 50 mM potassium chloride) containing 1 mg / mL of Aspergillus flavus-derived UOX to a 100 mL reagent bottle, and place it at 4 °C.

[0107] Refined lecithin (0.012 g) with a purity greater than 98% was dissolved in 6 mL of isopropanol. Prepare lecithin derivative solution. The solution temperature was 4°C. 6 mL of the purified lecithin residue solution was added dropwise to the aforementioned UOX solution at a rate of 1 mL / min, and the solution obtained by stirring at 50 rpm for 4 hours was used as a reaction solution.

[0108] The reaction solution was added to a G-25 desalting column equilibrated with carbonate buffer (20 mM pH10 sodium carbonate-sodium bicarbonate buffer, 100 mM sodium chloride, 0.1% Tween-20) for desalting and buffer exchange. The obtained solution was added to an anion exchange ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
percent by volumeaaaaaaaaaa
Login to View More

Abstract

The invention provides a urate oxidase (UOX) composition used as a medical matrix and a preparation method thereof. The composition comprises combining a refined phosphatidylcholine residue (PC) on m amines of the urate oxidase, wherein the refined phosphatidylcholine residue is represented by a following general formula (I), m is an integer of 1-16, and the urate oxidase combined with the phosphatidylcholine residue is represented by PC-UOX. The medicinal composition uses PC-UOX, which is the urate oxidase amine combined by the refined phosphatidylcholine residue, as a main component, and is composed of PC-UOX(m) (m=1-16).

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing urate oxidase and a preparation method thereof, in particular to a pharmaceutical composition prepared by combining refined lecithin residues in urate oxidase (UOX) derived from microorganisms, animals and plants. Composition and its preparation method, refinement process, etc. Background technique [0002] Uric acid oxidase is an important enzyme in living organisms, which can metabolize uric acid with low solubility into allantoin with high solubility, and then excrete it through the excretory system to prevent the accumulation of high concentration of uric acid in the body. In the history of human evolution, due to mutations in the gene encoding urate oxidase, the human body cannot synthesize urate oxidase and degrade uric acid into allantoin. [0003] If there is a failure in excreting uric acid or producing uric acid for a long time, uric acid will accumulate in the body. Du...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/44A61K47/48C12N9/96A61P19/06
Inventor 陈静尤东超齐连权肖萱张伟强周丽莹
Owner BEIJING TIDE PHARMA